Van professionele vertalers, bedrijven, webpagina's en gratis beschikbare vertaalbronnen.
under behandling med angiox er set trombedannelse under gamma-brachyterapi-procedurer.
intra-procedural thrombus formation has been observed during gamma brachytherapy procedures with angiox.
gammakilder - anvendes hovedsageligt i industrien, til strålebehandling ved ekstern bestråling, til brachyterapi og til sterilisering
gamma sources – mainly used in industry, external beam radiotherapy, brachytherapy and sterilisation;
-hvis din behandling er en såkaldt beta -eller gamma-brachyterapi, vil lægen etablere særlig
· extra care will be taken if you are having radiation treatment in the vessels that supply blood to
den mest effektive metode til bekæmpelse af disse svulster er højdosis-brachyterapi, hvor strålingseksponeringen af raske organer og rask væv minimeres under strålebehandlingen af de maligne svulster.
the most effective method of controlling these tumours is high-dose-rate brachytherapy, which minimises exposure to radiation of healthy organs and tissues during radiation treatment of malignant growth.
nedenstående kriterier gælder for normal klinisk brug af stråleterapeutisk udstyr, men ikke (nødvendigvis) for behandlingsudstyr til brachyterapi, intraoperativ, dynamisk eller palliativ bestråling og til helkropsbestråling.
these criteria are valid for the normal clinical use of radiation therapy equipment and not (necessarily) for brachytherapy, intraoperative, dynamic, palliative and whole body radiation therapy equipment.
4. 4 og 4. 6) • præeksisterende hypercalcæmi • svært nedsat nyrefunktion • andre metaboliske knoglesygdomme end primær osteoporose (inklusiv hyperparatyreoidisme og pagets knoglesygdom) • uforklarlig, forhøjet alkalisk fosfatase • tidligere ekstern strålebehandling eller brachyterapi af skelettet • patienter med maligne lidelser i skelettet eller knoglemetastaser frarådes behandling med teriparatid.
• hypersensitivity to the active substance or to any of the excipients. • pregnancy and lactation (see section 4.4 and 4.6) • pre-existing hypercalcemia • severe renal impairment • metabolic bone diseases other than primary osteoporosis (including hyperparathyroidism and paget’ s disease of the bone) • unexplained elevations of alkaline phosphatase • prior external beam or implant radiation therapy to the skeleton • patients with skeletal malignancies or bone metastases should be excluded from treatment with teriparatide.
